(NASDAQ: STRO) Sutro Biopharma's forecast annual revenue growth rate of 9.67% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.48%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.37%.
Sutro Biopharma's revenue in 2025 is $62,043,000.On average, 6 Wall Street analysts forecast STRO's revenue for 2025 to be $4,468,325,096, with the lowest STRO revenue forecast at $2,754,784,374, and the highest STRO revenue forecast at $5,336,488,903. On average, 7 Wall Street analysts forecast STRO's revenue for 2026 to be $4,654,641,443, with the lowest STRO revenue forecast at $890,531,822, and the highest STRO revenue forecast at $11,075,099,419.
In 2027, STRO is forecast to generate $7,402,221,138 in revenue, with the lowest revenue forecast at $5,081,811,882 and the highest revenue forecast at $15,690,282,679.